TherapeuticsMD, Inc. (NASDAQ:TXMD) will be posting its quarterly earnings results on Wednesday, November 1st. Analysts expect TherapeuticsMD to post earnings of ($0.10) per share for the quarter.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Thursday, August 3rd. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. The firm had revenue of $4.25 million for the quarter, compared to the consensus estimate of $4.91 million. TherapeuticsMD had a negative net margin of 485.71% and a negative return on equity of 74.25%. The firm’s revenue was down 3.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.11) earnings per share. On average, analysts expect TherapeuticsMD to post $-0.42 EPS for the current fiscal year and $-0.31 EPS for the next fiscal year.

Shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) opened at 5.00 on Wednesday. TherapeuticsMD, Inc. has a 12-month low of $3.50 and a 12-month high of $8.30. The stock’s market cap is $1.02 billion. The company’s 50-day moving average is $4.89 and its 200-day moving average is $4.89.

In related news, Director Tommy G. Thompson purchased 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 30th. The stock was acquired at an average cost of $5.99 per share, for a total transaction of $29,950.00. Following the completion of the acquisition, the director now owns 3,555 shares in the company, valued at approximately $21,294.45. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 23.92% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is owned by of American Banking News. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at

Several brokerages have commented on TXMD. Oppenheimer Holdings, Inc. set a $10.00 target price on shares of TherapeuticsMD and gave the stock a “buy” rating in a report on Thursday, August 17th. Jefferies Group LLC reiterated a “buy” rating and issued a $15.00 target price on shares of TherapeuticsMD in a report on Friday, August 11th. Noble Financial reiterated a “buy” rating on shares of TherapeuticsMD in a report on Friday, August 4th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $33.00 target price on shares of TherapeuticsMD in a report on Tuesday, August 15th. Finally, Zacks Investment Research upgraded shares of TherapeuticsMD from a “sell” rating to a “hold” rating in a report on Thursday, August 10th. Two research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $14.88.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with's FREE daily email newsletter.